Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
368
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • FP7 figures updated in Sept; 2006 to reflect May/June 2006 commission proposal The Annual Report 2003 was published in August 2004, so it contains the latest available published data. The Figures for 2012 and 2013 include projections for Euratom as shown in the Commission proposal even though the Euratom FP will run only until 2011. Budget/execution figures are for commitments in current prices and reflect the real totals shown below. Figures for recent years are provisional. Real totals for FP1-6: 3.27 5.36 6.6 13.12 14.85 19.235 Original budgets for FP1-6 : 3.27 5.36 6.6 13.12 14.96 17.5
  • Mention money!
  • Mention money!
  • Mention money!

Transcript

  • 1. Hälsa Gunnar Sandberg [email_address]
  • 2. Main points
      • The 7 th Framework programme (FP7)
        • Rationale and approach
        • Basic principles
        • 3rd call for proposals
        • Funding opportunities
        • Factors for success
  • 3.
    • Part of the European Commission
    • 2 Objectives:
      • Develop European research policies and strategies in collaboration with EU Member States
      • Provide support to research through the ”Framework Programmes”
    What is DG Research
    • The Framework Programme (FP) is the European Union’s multi-annual research funding mechanism
  • 4. Budgets of the EU Framework Programmes 1984-2013 NB: Budgets in current prices. Source: Annual Report 2003, plus FP7 revised proposal
  • 5. Indicative breakdown (million €) Total = € 50.4 billion for 7 years (40% increase compared to FP6) ERC FP7 (2007-2013)
  • 6. Collaborative research across borders and other barriers
    • between countries :
      • multinational consortia, with at least 3 partners from 27 EU Member States ( MS ) + Associated Countries ( Albania, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey)
      • researchers from any country in the world can participate
      • However: researchers from highly industrialised countries outside Europe can rarely receive funding (i.e Australia, Canada, Japan, Korea, New-Zealand, USA)
    • between different types of organizations
      • Public & private sector: universities, research centres, large companies, small and medium-size enterprises (SMEs), etc. disciplines : multidisciplinary, translational research
  • 7.  
  • 8. Main policy drivers in the Health theme
    • Improving health of European citizens
    • Increasing competitiveness of European health-related industries and businesses
    • Addressing global health issues , e.g. emerging epidemics
    • Budget :
    • € 6.1 billion (19%) over 7 years (2007-2013)
    Both basic and applied research is supported
  • 9. Submission & evaluation Basic principles :
      • annual calls for proposals
      • eligibility check (partners, budgets, scope, deadline)
      • evaluation by panels of independent experts
      • 3 Evaluation criteria :
        • Science & Technology excellence
        • Implementation & Management
        • Dissemination & Impact
      • feedback: evaluation summary report (ESR).
      • negotiation: grant agreement, funding for 2-5 y.
  • 10. Funding schemes in the Health theme (3 rd call) F unding schemes lower limits upper limit min. partners Collaborative Projects (CP): Large-scale (CP-IP) €6m €12m ≥ 3 Medium-scale €3m €6m ≥ 3 Small-scale (CP-FP) up to €3m ≥ 3 Network of Excellence (NoE) up to €12m ≥ 3 Coordination action (CA) up to €1.5m ≥ 3 Support action (SA) up to €0.5m ≥ 1 NB : the limits for minimum and maximum requested EC grant and for the minimum number of partners are eligibility criteria !
  • 11. the Health theme: structure and content pillar 1: Biotechnology, generic tools & technologies for health pillar 2: Translating research for human health pillar 3: Optimising the delivery of health care cross-cutting issues: child health, the health of ageing population gender-related health issues Activity (pillar) 4: Other actions across the theme
  • 12. 3 rd call for proposals for the Health theme
      • Publication of 3 rd call expected: 3 September 2008
        • drawing on the budget for 2009: ~€ 591m
        • there will in fact be two calls, published in parallel:
          • ‘ FP7-HEALTH-2009-single-stage’ €476 m for most areas of the work programme expected deadline: 3 Dec. 2008
          • ‘ FP7-HEALTH-2009-two-stage’ €115 m only for areas 1.1 & 2.1. expected deadlines for 1 st stage: 3 Dec. 2008
          • indicative deadline for 2 nd stage 22 April 2009
    Based on proposals of European Commission services, subject to confirmation in call text.
  • 13. Introducing two-stage submission/evaluation
      • Only for areas 1.1 & 2.1
        • 1.1 – High-throughput research
        • 2.1 – Integrating biological data and processes (large-scale data-gathering and systems biology)
      • First stage :
        • proposal size limited to 8 pages
        • Evaluation of 2 criteria only (S/T quality and Impact)
      • Second stage :
        • only coordinators of proposals passing Stage 1 will be invited to submit full proposals for Stage 2
        • evaluation on all 3 criteria, independently from Stage 1.
  • 14. Two-stage evaluation: Topics
    • Area 1.1 High-throughput research
      • Computational tools for genome annotation and genotype/ phenotype data integration .
      • High throughput tools and technologies to analyse samples in large-scale human biobanks.
      • Tools & technologies for characterisation of protein functions.
    • Area 2.1 Large-scale data gathering & Systems biology
      • Large-scale functional genomics effort in multi-cellular organisms to elucidate the function of human genes products.
      • Large-scale functional genomics efforts to identify molecular determinants of cancer.
      • Characterisation of human genetic variation in Europe.
      • Systems biology approaches for basic biological processes
      • relevant to health and disease.
  • 15. Collaborative Health Research: Pillar 1
    • 1: Biotechnology, generic tools and technologies
    • High-throughput research – only 2-stage in 3rd call
    • Detection, diagnosis and monitoring
    • Predicting suitability, safety and efficacy of therapies – mainly implemented through Innovative Medicines Initiative (IMI)
    • Innovative therapeutic approaches and interventions
  • 16. 1.2 Detection, diagnosis and monitoring (1)
      • Topics proposed for 3 rd call:
      • Development of tools for sensitive and specific detection of proteins and their interactions for diagnostic purposes . Funding scheme: CP-FP, max. € 6m. (1 or more projects)
      • Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders. Funding scheme: CP-FP, max. € 3m (1 or more projects)
      • Novel MR-compatible PET detectors for simultaneous PET/MRI imaging . Funding scheme: CP-IP, max. € 12m. (max. 1 project)
  • 17. 1.2 Detection, diagnosis and monitoring (2)
      • Topics proposed for 3 rd call:
      • Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy . Funding scheme: CP-FP, max. € 6m. (max. 1 project)
      • Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases. Funding scheme: CP-FP, max. € 6m. (1 or more projects)
      • Evaluation of the potential health impact of diagnostic imaging agents doses (…with a focus on either radioactive or non-radioactive imaging agents). Funding scheme: Support Action, max. € 0.5m. ( max. 1 project for each area)
  • 18. 1.4 Innovative therapeutic approaches and interventions
      • Topics proposed for 3 rd call :
      • Regenerative medicine
      • Cell therapy for tissue and organs. Funding scheme: CP-IP, max. € 12m.
      • Regeneration of tissue using bio-compatible materials & cells . Funding scheme: CP-IP, max. € 12m.
      • Activation of endogenous cells as an approach to regenerative medicine. Funding scheme: CP-IP, max. € 12m.
    For these topics, which are all for large-scale integrating projects, more than one project may be funded per topic , provided they are of sufficient quality and depending on the EC budget available.
  • 19. Collaborative Health Research Pillar 2
    • 2: Translating research for human health
    • Integrating biological data and processes – only 2-stage in 3rd call
    • Research on the brain and related diseases, human development and ageing
    • Translational research in major infectious diseases
    • Translational research in other major diseases
  • 20. 2.2 – Research on Brain diseases human development and ageing
    • Topics in the 3 rd call:
      • Synaptopathies : genesis, mechanisms and therapy. Funding scheme: CP-IP, max. € 12m. (max. 1 project)
      • Identifying genetic and environmental interactions in schizophrenia . Funding scheme: CP-IP max. € 12m. (max. 1 project)
      • Optimising current therapeutic approaches to schizophrenia . Funding scheme: CP-IP, max. € 12m (max. 1 project)
      • Understanding the blood brain barrier to improve drug delivery to the brain. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
      • Psycho-social factors of brain disorders. Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)
      • NO TOPICS on Human Development and Ageing in 3rd call
  • 21. 2.3.1 – Infectious Diseases: Anti-microbial drug resistance
    • Topics proposed for 3 rd call:
      • Global collaborative research on the prevention of antibiotic resistance. Funding scheme: CP-IP, max. € 12m. (max. 1 project)
      • Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host . Funding scheme: CP-FP, max. € 6m. (1 or more projects)
      • Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers. Funding scheme: CP-FP, max. € 6m. (1 or more projects)
  • 22. 2.3.2 – Infectious Diseases: HIV/AIDS, malaria & TB
      • Topics proposed for 3 rd call:
      • Integration of European efforts in research on malaria. Funding scheme: Network of Excellence, max. € 12m. (max. 1 project)
      • Identification and pre-clinical testing of new vaccine candidates for tuberculosis. Funding scheme: CP-IP, max. € 12m. (max. 1 project)
      • Discovery and/or development of new and promising anti-HIV microbicides . Funding scheme: CP-IP, max. € 12m. (max. 1 project)
      • Mucosal and topical vaccines for poverty related diseases (HIV/AIDS, malaria and/or TB). Funding scheme: CP-IP, max. € 12m. (max. 1 project)
      • Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB). Funding scheme: CP-FP, max. € 3m. (max. 1 project)
  • 23. 2.3.3 – Potentially new and re-merging epidemics
      • Topic proposed for 3 rd call:
      • Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission. Funding scheme: CP-FP, max. € 3m. (max. 1 project)
  • 24. 2.3.4 Neglected infectious diseases
      • Topics proposed for 3 rd call : published under area 4.3.1
      • Discovery and development of new vaccines or drugs for helminth infections (SICA). Target region: ICPC. Funding scheme: CP-FP max. € 6m. (1 or more projects)
      • Identification and development of vaccine candidates for neglected bacterial infections (SICA). Target region: ICPC. Funding scheme: CP-FP max. € 6m. (1 or more projects)
      • Human Immune Responses to co-infections of Poverty-Related (HIV, malaria, TB) and Neglected Infectious Diseases (SICA). Target region: ACP. Funding scheme: CP-IP, max. € 12m. (max 1 project)
    SICA: Specific International Cooperation Action ICPC: International Cooperation Partner Countries ACP: African, Caribbean and Pacific countries
  • 25. 2.4.1 – Cancer
      • Temporary closure of this area
      • No topics in this call.
  • 26. 2.4.2 – Cardiovascular disease
      • Topics proposed for 3 rd call:
      • Improved or new therapeutic approaches for the treatment of heart failure . Funding scheme: CP-IP, max. € 12m. (max 1 project)
      • Cardiac arrhythmias : from genes to improved management of patients. Funding scheme: CP-IP, max. € 12m. (max 1 project)
      • Translation of basic knowledge on inherited cardiomyopathies into clinical practice. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
  • 27. 2.4.3 – Diabetes and obesity
      • Topics proposed for 3 rd call:
      • Novel therapeutical approach to pregnancy-induced diabetes. Funding scheme: CP-FP, max. € 3m. (max. 1 project)
      • Novel immunotherapies for type 1 diabetes. Funding scheme: CP-IP, max. € 12m. (max. 1 project)
      • Molecular pathways in food intake at CNS-liver-gut regulation level. Funding scheme: CP-FP, max. € 3m. (max. 1 project)
  • 28. Rare Diseases and Other Chronic Diseases
      • Topics for 2.4.4 – Rare Diseases :
      • Rare neurological diseases. Funding scheme: CP-FP, max. € 6m. (1 or more projects)
      • Preclinical development of substances with a clear potential as orphan drugs. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
      • Topics for 2.4.5 – Other chronic diseases :
      • Prevention and treatment of non-alcoholic fatty liver disease . Funding scheme: CP-FP, max. €6m. (1 or more projects)
      • Cellular and molecular mechanisms of development of chronic kidney disease (CKD). Funding scheme: CP-IP, max. € 12m. (max. 1 project)
  • 29.
    • 3: Optimising the delivery of healthcare
    • Translating clinical research into clinical practice
    • Quality, efficiency and solidarity of healthcare systems
    • Enhanced health promotion and disease prevention
    Collaborative Health Research: Pillar 3
  • 30. Collaborative research on the Health theme
    • 4. Actions across the Theme
    • Coordination & Support Actions across the theme
    • Responding to EU policy needs
    • Specific International Cooperation Actions (SICA)
  • 31. 4.1 Coordination and support actions across the theme
      • Topics proposed for 3 rd call:
      • Monitoring tool and technology transfer analysis for Health theme grants during FP7. Funding scheme: Support Action, max. € 1m. (max. 1 project)
      • Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers. Funding scheme: Coordination or Support Action, max. € 1m (1 or more projects)
      • Targeting publication bias. Funding scheme: Support Action, max. € 0.5m. (max. 1 project)
  • 32. 4.2 Responding to EU policy needs
      • Topics proposed for 3 rd call:
      • Adapting off-patent medicines to the specific needs of paediatric populations. Funding scheme: CP-FP, max. € 6m. (1 or more projects)
      • Study of the arrhythmogenic potential of different classes of medicines. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
      • Human papillomavirus vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease modelling and health economics. Funding scheme: CP-FP, max. € 3m. (max. 1 project)
      • Coordinating action on organ procurement & transplantation with a focus on new EU Member States. Funding scheme: Coordination Action, max. € 1.5m. (max. 1 project)
  • 33. 4.3 SICA Specific International Cooperation Actions
      • Topics proposed for 3 rd call:
      • Strategies for improving reproductive health . Target region: ICPC*. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
      • Access to medicines . Target region: ICPC*. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
      • Integration of disease surveillance and health systems response . Target region: ACP** or Asian countries. Funding scheme: CP-FP, max. € 3m. (1 or more projects)
      • Comparative population genetic studies on multifactorial diseases . Target region: Russia. Funding scheme: CP-FP, max. € 3m. (1 project)
      • D iabetic and weight-related co-morbidity in heart failure . Target region: Russia. Funding scheme: CP-FP, max. € 3m. (max. 1 project)
    *ICPC: International Cooperation Partner Countries **ACP: African, Caribbean and Pacific countries
  • 34. Key figures from last call
    • call: 2007-B (18 Sept. 2007)
      • budget : € 567 million (2008)
      • proposals received: 902
      • proposals evaluated: 865 (ineligible 37)
      • proposals to be funded : 167 % of proposals evaluated: 19%
      • av. grant per participant: €334,000
    Success rate: Sweden- 26% (vs Germany- 22%; Denmark- 28%)
  • 35. Other opportunities in FP7
    • Mainly through Collaborative Research, but also:
    • Innovative Medicines Initiative (IMI)
      • Joint public-private initiative between EFPIA and EC
    • European Research Council (ERC)
      • Grants to individual research groups
    • People Programme (Marie-Curie)
      • Individual fellowships
  • 36. IMI is a public-private partnership
    • Aim: To remove major bottlenecks and to provide with new “toolbox” to make the drug development process safer and more efficient.
    • re- invigorate the European bio-pharmaceutical sector
    • delivery of new approaches , tools, methods and technologies, improve knowledge management of research results and data, and support the training of professionals
    2 Billion EURO 1 Billion Euro 1 Billion Euro Public Private Partnership
  • 37.
    • Individual teams led by independent Principal Investigators are supported
    • Frontier Research Project: All fields of research are eligible
    • Peer Review Evaluation: Scientific excellence is the sole selection criterion (25 panels – 9 for LifeSciences)
    • 2 basic grant forms:
      • ERC Starting Independent Research Grant (2-9 years post PhD): up to € 2 million for 5 years. Deadline: Autumn 2008
      • ERC Advanced Investigator Grant : up to € 2.5 (3.5) million for 5 years. Deadline (LifeSciences): 22 April 2008
    Ideas Programme (European Research Council)
  • 38.
    • MC Initial Training Networks :
      • Participants: Network of at least 3 (universities, research centres, companies, SMEs),
      • Funding for: recruitment of early-stage researchers, visiting scholars, networking
    • Life-long training and career development ( individual fellowships for experienced researchers/postdocs)
      • Intra-European Fellowships for Career development (IEF), 12-24 months
      • European Reintegration grants (ERG), following a MC mobility action
      • Co-funding of Regional, National, and International Programmes (COFUND)
    People Programme (Marie Curie) (1)
  • 39.
    • Industry-academia partnerships and pathways ( IAPP ):
      • Participants: at least one academic and one industry/SME organisation from at least 2 different MS/AC
      • Funding for: exchange of know-how + experience through secondments, visiting scholars/trainers from outside partnership, networking (for 3-4 years)
      • Conference in Brussels on 14 Jan 2008: ftp://ftp.cordis.europa.eu/pub/fp7/people/docs/marie-curie-iapp-conference-140108_en.doc
    • International Dimension (individual fellowships for experienced researchers/postdocs)
      • International outgoing fellowships for career development (IOF)
      • International incoming fellowships (IIF)
      • MC international reintegration grants (IRG)
    People Programme (Marie Curie) (2)
  • 40. Priority setting – how are topics decided?
      • Conferences, workshops, reflection papers
      • Dedicated expert workshops
      • Important stakeholder organisations (WHO, ECDC)
      • Advisory Group (experts)
      • Commission services (support to EU policies)
      • Programme Committee (Member States)
  • 41.
      • Dan Andrée
      • Special Advisor
      • Ministry of Education and Research
      • “ A rough guide to the FP7 Work Programmes. Who can be involved in the preparation? What to do, when and how?”
      • Available at http://www.vinnova.se
  • 42. Information
    • Partnersökning; SMEsGo Health www.smesgohealth.org
    • Planeringsbidrag och SMINT
    • www.vinnova.se
    • Utlysningstext, EPSS etc
    • www.cordis.lu
  • 43. Hälsa Resultat
  • 44. Första utlysningen
    • Ansökningar totalt: 894 with Swedish participation: 231 with Swedish SME: 43 Prioriterade: 152 with Swedish participation: 56 with Swedish coordinator: 10 with Swedish SME: 11
  • 45. Andra utlysningen prel efter start av SME Support Office
    • Ansökningar totalt: 897 with Swedish participation: nd with Swedish SME: 58 Prioriterade: 172 with Swedish participation: 90 with Swedish coordinator: 11 with Swedish SME: 15
  • 46. Thank you
  • 47. Advantages of EC Research Projects
    • Networking with others
      • Access to large pool of know-how
      • within the consortium
    • Financial benefit
      • Contribution from EC
      • Few strings attached
    • Quality stamp
      • Tough selection procedure
      • Leverage for additional funding
  • 48. Risks of joining EC Research Projects
    • Competition
      • Competition is tough – the proposal and partners must be excellent
    • Partnership principle
      • Ownership and decision in partnership
    • Bureaucracy
      • Paper work and guidelines (But maybe not that bad)
    • Financial risk
      • Co-funding required (25-50%)
      • Cash-flow problems (pre/post-payments and delays)
  • 49. The Evaluation process Eligibility Final decision and procedures Panel Submission Consensus meeting in Brussels Remote individual evaluation Finalisation COMMISSION COMMISSION EXPERTS Evaluation
  • 50.
    • Start well in advance
    • Be clear of what you want and what is requested in the call: if the two do not fit, do not bother… (it shows!)
    • Make sure the proposal addresses the call text fully (topic and overall objective of the area – read the workprogramme introduction!)
    • Think European (what added value will this proposal bring to Europe?)
    • Where do I find those SME s? (SMEsgoHealth)
    • Geographical balance… (truths and myths)
    • Make sure your partners are fully committed to the project (and not only to obtaining financial support to continue doing what they always did)
    • Contact your NCP / University EU Liaison office to learn from their experience, get tips and the latest news
    Strategic Planning (I)
  • 51.
    • Download and READ the relevant documents before you start to write:
      • Workprogramme (including introduction and annexes)
      • Guide for proposers
    • Be aware of eligibility criteria:
      • Proposal submitted on time (before 17:00 the day of the dead-line, NOT 17:01!!) with margins –there may be unforeseen technical problems
      • Respect the budget brackets for the funding scheme (1 € outside the range – above or below! - and the proposal will not even be evaluated!)
      • Minimum (number) legal participants
      • Don‘t mix single and 2 stage topics, where applicable
    Strategic Planning (II)
  • 52.
    • Be clear on the evaluation criteria and thresholds*
    • Section A – Formalities (try to be accurate!)
    • Section B – The actual proposal text (evaluation criterion Relevance of FP6 is now incorporated into Science)
        • B1- Science 3*/5 – 33%
        • B2 – Implementation 3*/5 - 33%
        • B3 – Impact 3*/5 - 33%
        • Overall – 10*/15
    • *may change from call to call….
    Strategic Planning (III)
  • 53. Importance of the IMPACT section as a proposal differentiator
    • A typical proposal from academics will have:
        • 60 pages of wonderful science
        • 12 pages of wonderful colleagues and management
        • 2 pages of IMPACT – mostly repeating the introduction of B1 saying:
          • X million people suffer from this disease
          • We will create a vaccine…
  • 54. What should the IMPACT section be about?
    • What will really happen if the project is successful e.g. The new vaccine:
      • Somebody has to pay for Phase II, II and IV clinical trials – where will that money come from?
      • What regulatory hurdles must be overcome – who will overcome them?
      • Will the new vaccine be licensed to a large enterprise pharma (preferably one in your consortium) that will provide a route to market?
      • How will you convince pharma to take your vaccine?
        • What competition is already out there?
        • What differentiates your vaccine from all the others?
  • 55. How to describe the steps needed to meet the Expected Targets
    • What would you do in the ‘real world’ to achieve those targets? = exploitation and dissemination
    • Say that you will start E&D activities right from the Kick-Off Meeting (c.f. the vaccine example earlier)
    • Dissemination:
      • to whom?
      • at what conferences?
      • in what workshops?
      • over the internet?
      • in a new or extended partnership?
  • 56. Handling intellectual property issues in the proposal and in the post-project world
    • Intellectual property (IP) is not just patents – but what is it?
    • Tell the evaluators so that they know you know
    • Distinguish background and foreground IP
    • Tell the evaluators what foreground IP you think will be created in the project
    • Tell them how you will protect it
    • Tell them how you will use it to get your e.g. vaccine, to market